Diabetes Mellitus, Type 2, Healthy Volunteers
Conditions
Brief summary
This study is testing a new medicine that might help treat people with type 2 diabetes. The purpose of the study is to see if the new study medicine is safe and how well is tolerated by the body. There will be two groups of participants in this study: healthy participants and participants with type 2 diabetes. Participant will either get study medicine (NNC1679-0001) or placebo (a treatment that has no active medicine in it). NNC1679-0001 is a new experimental medicine that doctors cannot prescribe yet. Which treatment the participant gets is decided by chance. Participant will get one dose which will be injected into the area around abdomen (belly) by the medical staff.
Interventions
DRUGNNC1679-0001
NNC1679-0001 will be administered subcutaneously.
DRUGPlacebo
Placebo will be administered subcutaneously.
Sponsors
Novo Nordisk A/S
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Sponsor staff involved in the clinical trial is masked according to company standard procedures.
Eligibility
Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
Yes
Inclusion criteria
All participants * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine eligibility for the study. * Male or female (sex at birth) of nonchildbearing potential. * Age 18-64 years (both inclusive) at the time of signing the informed consent. Healthy participants * Body mass index (BMI) 18.5-29.9 kilograms per square meter (kg/m\^2) (both inclusive) at screening. * Glycated haemoglobin (HbA1c) lesser than or equal to (\<=) 6.4 percent (%) (47 \[millimoles per mole\] mmol/mol) at screening. * Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiograms (ECG), and clinical laboratory tests performed during the screening visit, as judged by the investigator. Participants with Type 2 Diabetes Mellitus (T2DM) * BMI 20.0-34.9 kg/m\^2 (both inclusive) at screening. * HbA1c 6.5-9.0% (47.5-74.9 mmol/mol) at screening. * Diagnosed with T2DM greater than or equal to (\>=)180 days before screening. * Stable (as judged by the investigator) daily dose(s) of metformin or combination of metformin and dipeptidyl peptidase IV (DPP-4) inhibitors and/or sodium-glucose co-transport 2 SGLT 2) inhibitors \>= 90 days before screening.
Exclusion criteria
All participants * Screening alanine aminotransferase (ALT) values greater than (\>) upper limit of normal (ULN) +10%, aspartate aminotransferase (AST) values \>ULN +20%, or total bilirubin \>ULN. * Renal impairment, defined as estimated glomerular filtration rate (eGFR) \<60.0 milliliter per minute per 1.73 square meter (mL/min/1.73m\^2), at screening. * Clinical evidence of chronic kidney disease (CKD) and/or urinary albumin: creatinine ratio (UACR) \>30 milligrams per gram (mg/g). * Presence or history of cardiovascular disease, including stable and unstable angina pectoris, myocardial infarction, transient ischaemic attack, stroke, cardiac decompensation, clinically significant arrhythmias, or clinically significant conduction disorders. Healthy participants * Any disorder that, in the investigator's opinion, might jeopardise participants' safety or compliance with the protocol. * Supine blood pressure at screening outside the range of 90-139 millimeters of mercury (mmHg) for systolic or 50-89 mmHg for diastolic. Participants with T2DM * Any disorder except for mild conditions under stable treatment associated with T2DM, which in the investigator's opinion might jeopardise participant safety or compliance with the protocol. * Supine blood pressure at screening outside the range of 90-159 mmHg for systolic or 50-99 mmHg for diastolic. This exclusion criterion also pertains to those participants who are receiving antihypertensive treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Treatment-Emergency Adverse Events (TEAEs) | From dosing (day 1) upto week 34 | Measured in events. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of TEAEs | From dosing (day 1) until V15a/V15b (week 26) | Measured in events. |
| Number of hypoglycaemic episodes | From dosing (day 1) upto week 34 | Measured in episodes. |
| AUC: The area under the NNC1679-0001 plasma concentration-time curve from time zero to the last measurable concentration after a single dose | From dosing (day 1) upto day 3 or day 15 | Measured in hours\*nanograms per milliliter (hour × ng/mL). |
| Cmax: The maximum concentration of NNC1679-0001 in plasma after a single dose | From dosing (day 1) upto day 3 or day 15 | Measured in nanograms per milliliter (ng/mL). |
| tmax: The time from dosing to maximum plasma concentration of NNC1679-0001 after a single dose | From dosing (day 1) upto day 3 or day 15 | Measured in hours. |
| t1/2: Terminal half-life for NNC1679-0001 after a single dose | From dosing (day 1) upto day 3 or day 15 | Measured in hours. |
| CLR: Renal clearance of NNC1679-0001 after a single dose | From dosing (day 1) upto day 3 | Measured in liter per hours (L/hours). |
Countries
Austria
Contacts
CONTACTNovo Nordisk
STUDY_DIRECTORClinical Transparency dept. 2834
Novo Nordisk A/S
Outcome results
None listed